Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
Sun Yat-sen University · Sun Yat-sen University Cancer Center · +27 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
475
total citations
- FWCI
- 45.04
- Percentile
- 100%
- References
- 19
Citations per year
Authors
25- FWF. Wang
Sun Yat-sen University, Sun Yat-sen University Cancer Center
- XWXiaoli Wei
Sun Yat-sen University, Sun Yat-sen University Cancer Center
- FWFenggong Wang
Sun Yat-sen University, Sun Yat-sen University Cancer Center
- NXNong Xu
Zhejiang University
- LSLin Shen
Peking University, Peking University Cancer Hospital
Topics & keywords
Topics
Keywords
- Medicine
- Refractory (planetary science)
- Clinical trial
- Oncology
- Cancer
- Internal medicine
- Phases of clinical research
- Biomarker
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.